Radius Health Inc RDUS:NASDAQ

Last Price$21.06Cboe Real-Time Last Sale as of 10:39AM ET 5/24/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.42(2.03%)
Bid (Size)$20.92 (75)
Ask (Size)$21.05 (85)
Day Low / High$20.79 - 21.20
Volume32.2 K

View Biotechnology IndustryPeer Comparison as of 05/24/2019


Radius Health Inc ( NASDAQ )

Price: $21.06
Change: +0.42 (2.03%)
Volume: 32.2 K
10:39AM ET 5/24/2019

NanoString Technologies Inc ( NASDAQ )

Price: $27.56
Change: +0.70 (2.61%)
Volume: 39.6 K
10:43AM ET 5/24/2019

Omeros Corp ( NASDAQ )

Price: $19.17
Change: +0.19 (1.00%)
Volume: 56.6 K
10:27AM ET 5/24/2019

Alder Biopharmaceuticals Inc ( NASDAQ )

Price: $11.17
Change: +0.16 (1.45%)
Volume: 25.0 K
10:42AM ET 5/24/2019

Luminex Corp ( NASDAQ )

Price: $20.98
Change: +0.58 (2.84%)
Volume: 44.4 K
10:43AM ET 5/24/2019

Read more news Recent News

Insider Trends: 90-Day Insider Buying Trend at Radius Health Reduced with Sale of Shares
4:13PM ET 4/19/2019 MT Newswires

Kurt Graves, Director, reported a sale of 4,800 shares in Radius Health (RDUS) on Apr 16, 2019, for $107,136. Following the Form 4 filing with the SEC,...

Insider Trends: Radius Health Insider Sale Scales Back 90-Days of Buys
4:16PM ET 4/12/2019 MT Newswires

Dr Debasish Roychowdhury, Director, reported a sale of 4,800 shares in Radius Health (RDUS) on Apr 11, 2019, for $106,320. After the Form 4 filing with...

Radius Health Says Analysis Suggests Abaloparatide Useful For Treating Postmenopausal Osteoporosis, Osteoarthritis
8:45AM ET 3/25/2019 MT Newswires

Radius Health (RDUS) said Saturday that it presented a post-hoc analysis of phase 3 data from different patient populations in its Active trial, as well as...

Insider Trends: Insider Purchase of Radius Health Stock Extends 90-Day Positive Trend
4:33PM ET 3/06/2019 MT Newswires

Jessica Hopfield, Director, on Mar 05, 2019, made a purchase of 12,800 shares in Radius Health (RDUS) for $246,190. Following the Form 4 filing with the...

Company Profile

Business DescriptionRadius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA. View company web site for more details
Address950 Winter Street
Waltham, Massachusetts 02451
Number of Employees398
Recent SEC Filing05/13/20194
President, Chief Executive Officer& DirectorJesper Høiland
CFO, Treasurer, Principal Accounting Officer & SVPJose Carmona
Chief Medical OfficerCharles Q. Morris
Vice President-Technical OperationsChhaya Shah

Company Highlights

Price Open$20.77
Previous Close$20.64
52 Week Range$12.81 - 31.92
Market Capitalization$971.0 M
Shares Outstanding46.1 M
SectorHealth Technology
Next Earnings Announcement08/06/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.42
Beta vs. S&P 500N/A
Revenue$99.2 M
Net Profit Margin-176.84%
Return on Equity-252.83%

Analyst Ratings as of 05/17/2019

Consensus RecommendationConsensus Icon
Powered by Factset